Intervention of Interest
- brensocatib (Brinsupri, Insmed Incorporated)
For questions please contact [email protected].
View the Key Stakeholder List.
Independent appraisal committee voted unanimously on the positive net health benefit of brensocatib; but current pricing represents “low” value for money.
Final Documents
ICER’s Chief Scientific Officer and Director of Health Technology Assessment Methods and Engagement Dan Ollendorf, PhD, MPH stated:
“Brensocatib provides a clear benefit to patients dealing with NCFB, who have waited a long time for a therapy targeted to their condition. Yet there are significant uncertainties regarding the extent of brensocatib’s benefits, and its current price does not align with even the most optimistic take on those benefits. Manufacturers must responsibly price new therapies like brensocatib so that patients have fair access to those therapies and a sustainable health care system for everyone.”
Public Comments
Closed